nach oben

Erschienen in:

30.10.2017 | Review

Association Between Adipokines Levels with Inflammatory Bowel Disease (IBD): Systematic Reviews

verfasst von: Nava Morshedzadeh, Mehran Rahimlou, Hamid Asadzadeh Aghdaei, Shabnam Shahrokh, Mohammad Reza Zali, Parvin Mirmiran

Erschienen in: Digestive Diseases and Sciences | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

A combination of genetic and environmental factors is involved in the etiology of inflammatory bowel disease (IBD). Recent studies have shown that adipocytes play a crucial role, by actively participating in systemic immune responses in IBD patients. But findings remain controversial. To the best of our knowledge, no systematic review has evaluated the roles of adipokines in IBD, considering which this systematic review was undertaken to summarize the effects of these adipokines in IBD pathogenesis.

Methods

For this review, articles published between 1980 and 2016 were identified from the PubMed, EMBASE, Scopus, and Cochrane and Google scholar databases. Thirteen articles were ultimately selected for inclusion in this systematic review.

Results

Findings of the present study indicate that some of the adipokines such as leptin, adiponectin and resistin are associated with disease severity, body composition and glucose hemostasis in IBD patients, although some of these associations are stronger than others.

Conclusions

Overall findings indicate that some adipokines may play a crucial role in IBD severity or other IBD related outcomes. Further studies are recommended to confirm the results.

Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182–205.CrossRefPubMed

Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205–217.CrossRefPubMed

Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg. 1998;22:382–389.CrossRefPubMed

Ghigliotti G, Barisione C, Garibaldi S, et al. Adipose tissue immune response: novel triggers and consequences for chronic inflammatory conditions. Inflammation. 2014;37:1337–1353.CrossRefPubMedPubMedCentral

Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85–97.CrossRefPubMedPubMedCentral

Paz-Filho G, Mastronardi C, Franco CB, Wang KB, Wong M-L, Licinio J. Leptin: molecular mechanisms, systemic pro-inflammatory effects, and clinical implications. Arq Bras Endocrinol Metabol. 2012;56:597–607.CrossRefPubMed

Barbier M, Vidal H, Desreumaux P, et al. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol. 2003;27:987–991.PubMed

Singh UP, Singh NP, Guan H, et al. The emerging role of leptin antagonist as potential therapeutic option for inflammatory bowel disease. Int Rev Immunol. 2014;33:23–33.CrossRefPubMed

Ruan H, Dong LQ. Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol.. 2016;8:101–109.CrossRefPubMedPubMedCentral

10.

Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380:24–30.CrossRefPubMedPubMedCentral

11.

Ghomraoui FA, Alotaibi ST, Alharthi MA, et al. Plasma ghrelin and leptin in patients with inflammatory bowel disease and its association with nutritional status. Saudi J Gastroenterol. 2017;23:199–205. PubMed PMID: 28611344. Pubmed Central PMCID: PMC5470380. Epub 06/15/2017. eng.

12.

Al-Suhaimi EA, Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res. 2013;18:12.CrossRefPubMedPubMedCentral

13.

Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178:1748–1758.CrossRefPubMed

14.

Terzoudis S, Malliaraki N, Damilakis J, Dimitriadou DA, Zavos C, Koutroubakis IE. Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2016;28:814–819.CrossRefPubMed

15.

Laiguillon M-C, Houard X, Bougault C, et al. Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis. Arthritis Res Ther. 2014;16:R38.CrossRefPubMedPubMedCentral

16.

Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8:2–10. PubMed PMID: 25594108. Epub 01/17/2015. eng.

17.

Aurangzeb B, Leach ST, Lemberg DA, Day AS. Assessment of nutritional status and serum leptin in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;52:536–541.CrossRefPubMed

18.

Bannerman E, Davidson I, Conway C, Culley D, Aldhous M, Ghosh S. Altered subjective appetite parameters in Crohn’s disease patients. Clin Nutr. 2001;20:399–405.CrossRefPubMed

19.

Tuzun A, Uygun A, Yesilova Z, et al. Leptin levels in the acute stage of ulcerative colitis. J Gastroenterol Hepatol. 2004;19:429–432.CrossRefPubMed

20.

Rodrigues V, Milanski M, Fagundes J, et al. Serum levels and mesenteric fat tissue expression of adiponectin and leptin in patients with Crohn’s disease. Clin Exp Immunol. 2012;170:358–364.CrossRefPubMedPubMedCentral

21.

Valentini L, Wirth EK, Schweizer U, et al. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease. Nutrition. 2009;25:172–181.CrossRefPubMed

22.

Dogan S, Guven K, Celikbilek M, Deniz K, Saraymen B, Gursoy S. Serum visfatin levels in ulcerative colitis. J Clin Lab Anal. 2015;30:552–556.CrossRefPubMed

23.

Konrad A, Lehrke M, Schachinger V, et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol. 2007;19:1070–1074.CrossRefPubMed

24.

Weigert J, Obermeier F, Neumeier M, et al. Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn’s disease. Inflamm Bowel Dis. 2010;16:630–637.CrossRefPubMed

25.

Chouliaras G, Panayotou I, Margoni D, et al. Circulating leptin and adiponectin and their relation to glucose metabolism in children with Crohn’s disease and ulcerative colitis. Pediatr Res. 2013;74:420–426.CrossRefPubMed

26.

Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:100–105.CrossRefPubMed

27.

Abdel Kader N, Ali El-Din F, Khatab EA, ELAbd N. Does plasma resistin level have a role in predicting inflammatory bowel disease activity? Indian J Gastroenterol. 2010;29:126–127.CrossRef

28.

Ahishali E, Ercan S, Dolapcioglu C, Dabak R, Kaptanagasi A, Bayramicli O. P140 The relation between resistin and insulin resistance in inflammatory bowel disease patients. J Crohn’s Colitis. 2012;6:S65–S66.CrossRef

29.

Bruun JM, Pedersen SB, Kristensen K, Richelsen B. Effects of pro-inflammatory cytokines and chemokines on leptin production in human adipose tissue in vitro. Mol Cell Endocrinol. 2002;190:91–99.CrossRefPubMed

30.

Franchimont D, Roland S, Gustot T, et al. Impact of infliximab on serum leptin levels in patients with Crohn’s disease. J Clin Endocrinol Metab. 2005;90:3510–3516.CrossRefPubMed

31.

Tiaka EK, Manolakis AC, Kapsoritakis AN, Potamianos SP. Unraveling the link between leptin, ghrelin and different types of colitis. Ann Gastroenterol. 2011;24:20–28. PubMed PMID: 24714276. Pubmed Central PMCID: PMC3959465. Epub 01/01/2011. eng.

32.

Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch. 2007;455:479–492. PubMed PMID: 17609976. Pubmed Central PMCID: PMC2040175. Epub 07/05/2007. eng.

33.

Neumeier M, Weigert J, Schäffler A, et al. Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol. 2006;79:803–808.CrossRefPubMed

34.

Yamaguchi N, Argueta JGM, Masuhiro Y, et al. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett. 2005;579:6821–6826.CrossRefPubMed

35.

Kaser A, Tilg H. “Metabolic aspects” in inflammatory bowel diseases. Curr Drug Deliv. 2012;9:326–332.CrossRefPubMed

36.

Paul G, Schäffler A, Neumeier M, et al. Profiling adipocytokine secretion from creeping fat in Crohn’s disease. Inflamm Bowel Dis. 2006;12:471–477.CrossRefPubMed

37.

Kaser S, Kaser A, Sandhofer A, Ebenbichler C, Tilg H, Patsch J. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun. 2003;309:286–290.CrossRefPubMed

38.

Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-α and IL-12 in macrophages by NF-κB-dependent pathway. Biochem Biophys Res Commun. 2005;334:1092–1101.CrossRefPubMed

39.

Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006;580:2917–2921.CrossRefPubMed

40.

Koutroubakis IE, Oustamanolakis P, Malliaraki N, et al. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2009;21:283–288.CrossRefPubMed

41.

Scoville AE, Brown C, Allaman M, et al. Differences in serum adipokines between Crohn’s disease and ulcerative colitis patients indicate that they may represent non-invasive biomarker. Gastroenterology. 2016;150:380–389.CrossRef

Titel: Association Between Adipokines Levels with Inflammatory Bowel Disease (IBD): Systematic Reviews
verfasst von: Nava Morshedzadeh
Mehran Rahimlou
Hamid Asadzadeh Aghdaei
Shabnam Shahrokh
Mohammad Reza Zali
Parvin Mirmiran
Publikationsdatum: 30.10.2017
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 12/2017
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-017-4806-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2017

Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease

Androgen Signaling in Esophageal Adenocarcinoma Cell Lines In Vitro

Enteric Glial Dysfunction Evoked by Apolipoprotein E Deficiency Contributes to Delayed Gastric Emptying

A Prospective Evaluation of Ileocecal Valve Dysfunction and Intestinal Motility Derangements in Small Intestinal Bacterial Overgrowth

Specialty Care Access Network-Extension of Community Healthcare Outcomes Model Program for Liver Disease Improves Specialty Care Access